May 25, 2011
/PRNewswire/ -- Rules-Based Medicine (RBM), a global leader in biomarker testing services, and its subsidiary, Psynova Neurotech, has achieved a significant milestone in a companion diagnostic development program with Roche. Using samples from a Roche clinical trial, the RBM DiscoveryMAP® platform, and Psynova's biomarker database and expertise, a biomarker pattern was identified that has utility in prognosis of disease progression and/or predicting or monitoring the efficacy for a compound in the Roche CNS pipeline. Roche has exercised its option to continue commercial development based on these results, which could result in additional future milestone and royalty payments to RBM/Psynova.
"Achieving this milestone is an example of how pharmaceutical and biotechnology companies can leverage RBM's testing services, databases, and expertise to make real progress," said
, President and CEO of RBM. "We appreciate the opportunity to work with a company of Roche's stature and experience to develop a product that both meets Roche's needs and can potentially improve patient outcomes. RBM values this relationship with a company that is leading the way and shares our vision for personalized healthcare"
This project highlights Rules-Based Medicine's
Strategic Biomarker Services
. RBM consults with our partners to design the best clinical trial, using our comprehensive menu of quantitative immunoassays and decades of expertise in sample type selection, experimental design, and data analysis.
April 27, 2011
, Myriad Genetics (Nasdaq: MYGN) of
Salt Lake City
, a leader in molecular diagnostics, announced an agreement to acquire Rules-Based Medicine. The transaction is expected to be complete by
May 31, 2011
. RBM headquarters will remain in
and will operate as a wholly owned subsidiary of Myriad Genetics under the name Myriad RBM.
About Rules-Based Medicine, Inc.
Rules-Based Medicine's biomarker testing service provides clinical researchers, physicians and healthcare providers with reproducible, quantitative, multiplexed data for hundreds of proteins to advance drug development and patient care. The Company's proprietary Multi Analyte Profiling (MAP) technology offers pre-clinical and clinical researchers broad, cost-effective protein analyses in multiple species from a small sample volume. MAP technology also supports RBM's drive to develop diagnostics that aid in the detection of complex diseases and conditions in areas of unmet medical need such as neuropsychiatry, nephrology, immunology and cardiology. RBM's initial molecular diagnostic test, VeriPsych™, is a blood-based test that aids in the confirmation of diagnosis of recent-onset schizophrenia by evaluating a proprietary set of 51 biomarkers. RBM also offers innovative and proprietary ex vivo testing systems such as TruCulture™, the first fully-closed, reproducible whole blood culture system. More information about RBM is located at
SOURCE Rules-Based Medicine, Inc.